Effect of nesiritide on length of hospital stay in patients with decompensated heart failure

Chang, Richard; Elatre, Wafaa A.; Heywood, J. Thomas
September 2004
Journal of Cardiovascular Pharmacology & Therapeutics;Sep2004, Vol. 9 Issue 3, p173
Academic Journal
journal article
We examined the effect of nesiritide, administered as initial therapy, on length of hospital stay (LOS) and renal function through a retrospective analysis of 129 consecutive admissions to the coronary care unit in 98 patients diagnosed with congestive heart failure. Nesiritide was infused during 58 admissions (nesiritide group) while other therapies, not including nesiritide, were used during 71 admissions (non-nesiritide group). Although the nesiritide group showed lower baseline left ventricular ejection fraction and systolic blood pressure, higher serum creatinine, and a longer QRS interval, the LOS of this group was significantly shorter compared to the non-nesiritide group (3.91 +/- 1.3 vs 4.77 +/- 1.7 days, P = .0023). Both groups were similar with respect to body weight change (negative fluid balance), a slight decrease in blood urea nitrogen, and unchanged serum creatinine. Nesiritide as an initial therapy for treatment of congestive heart failure results in a more rapid hospital discharge without compromising renal function.


Related Articles

  • B-Type Natriuretic Peptide and Congestive Heart Failure. Faubion, Deborah A. // Clinical Laboratory Science;Winter2004, Vol. 17 Issue 1, p53 

    Discusses the use of B-type natriuretic peptides (BNP) to diagnose congestive heart failure. Information on the occurrence of CHF in the U.S. as of 2004; Characteristics of BNP; Benefits of BNP level measurement for patients with CHF. INSET: Dao Q, and others. Utility of B-type natriuretic...

  • A Basic Guide to Understanding Plasma B-Type Natriuretic Peptide in the Diagnosis of Congestive Heart Failure. Kreiger, Gretchen // MEDSURG Nursing;Apr2007, Vol. 16 Issue 2, p75 

    Congestive heart failure (CHF) affects millions of Americans and is responsible for the highest number of annual hospital admissions (Braunwald, 2005). Recent developments have occurred regarding clinical markers used in diagnosing CHF, including plasma B-type natriuretic peptide (BNP). In this...

  • Examining the uses of BNP testing in the outpatient setting. Harrison, Alex // Patient Care;Aug2005, Vol. 39 Issue 8, p38 

    Focuses on an investigation launched to explore the use of B-natriuretic peptide (BNP) values in the outpatient setting. Association of the perceived severity of congestive heart failure (CHF) with BNP levels according to the Rapid Emergency Department Heart Failure Outpatient Trial; Potential...

  • NOBEX and Biocon to Codevelop Oral Peptide for Treating Congestive Heart Failure. Rios, Maribel // Pharmaceutical Technology;Oct2005, Vol. 29 Issue 10, p28 

    Reports that Nobex Corp. and Biocon Ltd. will codevelop an oral formulation of human brain-type natriuretic peptide (hBNP) for the treatment of congestive heart failure. Terms of agreement; Oral bioavailability of hBNP.

  • Discovery of New Cardiovascular Hormones for the Treatment of Congestive Heart Failure. Vesely, David L. // Cardiovascular & Haematological Disorders - Drug Targets;Mar2007, Vol. 7 Issue 1, p47 

    In 1628, Harvey first correctly described the heart as a pump. It was another 350 years before the heart was established as an endocrine gland that synthesized a family of peptide hormones that regulate blood volume and blood pressure. There are now five peptide hormones made in the heart which...

  • Inverse association of long-acting natriuretic peptide with metabolic syndrome in congestive heart failure patients. Wang, Ji-Hung; Lee, Chung-Jen; Hsieh, Jen-Che; Chen, Yu-Chih; Hsu, Bang-Gee // Diabetology & Metabolic Syndrome;2013, Vol. 5 Issue 1, p1 

    Aims: Long-acting natriuretic peptide (LANP) is one of the peptide hormones in atrial natriuretic peptide (ANP) prohormone. Low levels of natriuretic peptide may lead to reduced lipolysis and excessive weight gain in obese patients. The aim of this study was to investigate the relationship...

  • Atrial natriuretic peptide kinetic studies in patients with cardiac dysfunction. Hensen, Johannes; Abraham, William T.; Lesnefsky, Edward J.; Levenson, Benny; Groves, Bertron M.; Schröder, Klaus; Schrier, Robert W.; Dürr, Jacques // Kidney International;May1992, Vol. 41 Issue 5, p1333 

    Three studies were performed: (1) a controlled investigation of α-human atrial natriuretic pepltide (α-hANP) lolal body production and metabolic clearance rates using a bolus infusion technique (controls, patients 1 to 6); (2) a study of α-hANP kinetics in cardiac dysfunction patients...

  • Laparoscopic versus open liver resection for hepatocellular carcinoma in posterosuperior segments. Xiao, Le; Xiang, Lun-jian; Li, Jian-wei; Chen, Jian; Fan, Yu-dong; Zheng, Shu-guo // Surgical Endoscopy;Oct2015, Vol. 29 Issue 10, p2994 

    Background: Traditional open liver resection remains the classic procedure for hepatocellular carcinoma (HCC) located in the posterosuperior segments of the liver (segments I, IVa, VII, and VIII). This study compared the perioperative and oncologic results for laparoscopic versus...

  • Natriuretic peptides associated with adiponectin production in HF. Raible, Eric // Cardiology Today;Jul2009, Vol. 12 Issue 7, p20 

    The article discusses a study on the association between natriuretic peptides and the production of adiponectin, a protein, in patients with congestive heart failure (HF).


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics